Risk factor
Strong trading liquidity
Profitability factor
Very strong margins and returns
About
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBIT
Target Price
The average target price of VRTX is 489 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
Buy
Sell